Sim­mer­ing feud be­tween blue­bird and a ri­val con­tin­ues with al­le­ga­tions of patent fraud

Blue­bird bio was hit with a patent in­fringe­ment law­suit last week from a Chica­go-based biotech it has had an on­go­ing beef with call­ing for $2 bil­lion to help cure the “ir­repara­ble harm” caused by al­leged will­ful in­fringe­ment.

Blue­bird bio is fac­ing a law­suit from Er­rant Gene Ther­a­peu­tics for vi­o­lat­ing patent law in two in­stances, the com­pa­ny says.

The suit al­leges that blue­bird in­fringed the rights of EGT’s re­com­bi­nant vec­tors used in the gene ther­a­py treat­ment of rare dis­eases such as sick­le cell dis­ease and be­ta tha­lassemia for its drugs Zyn­te­glo and Lenti­Glo­bin. EGT has an ex­clu­sive li­cense from the Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter to patents ti­tled “vec­tor en­cod­ing hu­man glob­al gene and use there­of in treat­ment of He­mo­glo­binopathies.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN